|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8048917||AZURITY||Prodrugs of GABA analogs, compositions and uses thereof|| |
(10 months ago)
|US6818787||AZURITY||Prodrugs of GABA analogs, compositions and uses thereof|| |
(1 year, 6 months from now)
|US8026279||AZURITY||Crystalline form of γ-aminobutyric acid analog|| |
(3 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8686034||AZURITY||Crystalline form of γ-aminobutyric acid analog|| |
(1 year, 3 months from now)
|US8114909||AZURITY||Treating or preventing restless legs syndrome using prodrugs of GABA analogs|| |
(2 years from now)
|US8795725||AZURITY||GABA analog prodrug sustained release oral dosage forms|| |
(5 years from now)
Horizant is owned by Azurity.
Horizant contains Gabapentin Enacarbil.
Horizant has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Horizant are:
Horizant was authorised for market use on 06 April, 2011.
Horizant is available in tablet, extended release;oral dosage forms.
Horizant can be used as treatment of moderate-to-severe primary restless leg syndrome in adults, management of postherpetic neuralgia (phn) in adults, treatment of moderate-to-severe primary restless leg syndrome in adults; management of postherpetic neuralgia (phn) in adults.
The generics of Horizant are possible to be released after 10 June, 2029.
Market Authorisation Date: 06 April, 2011
Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; Management of postherpetic neuralgia (phn) in adults
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic